- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06725251
The Impact of Art Therapy on the Relationships Between Individuals Diagnosed With Alzheimer's Disease and Their Care Partners
December 5, 2024 updated by: Wake Forest University Health Sciences
The purpose of this study is to evaluate the impact of a 4-week art therapy intervention on the relationships between individuals diagnosed with Alzheimer's disease and their care partners, on the self-esteem of diagnosed individuals, and on care partner attitudes towards persons with Alzheimer's disease.
Study Overview
Detailed Description
The aim is to develop and implement an art therapy intervention for dyads - each consisting of an individual diagnosed with mild Alzheimer's disease and his/her care partner - with the goals of improving patients' and care partners' sense of their relationship, increasing patients' self-esteem and improving care partner attitudes towards individuals with Alzheimer's disease.
The specific intervention will be a portrait-making project utilizing a collage approach.
Each participant (i.e.
diagnosed individuals and care partners) will be instructed to create a portrait of him/herself.
Participants will be provided with a sample portrait as well as bins of materials (e.g.
words, images, markers).
The intervention will be administered for 1 ½ hours weekly, at the same day/time, for 4 consecutive weeks.
Study Type
Interventional
Enrollment (Actual)
82
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Illinois
-
Park Ridge, Illinois, United States, 60068
- Advocate Memory Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion criteria for patients include:
- A diagnosis of Alzheimer's disease, based on the NIA/AA Diagnostic Guidelines for Alzheimer's Disease (McKhann et al., 2011)
- MMSE of 18-26, inclusive, administered within 6 month prior to screening or at screening
- Awareness of diagnosis and/or memory impairment, as determined by semi-structured interview with clinician (see Appendix B)
- Availability and willingness to participate in all 4 sessions of the intervention
- A care partner with whom the patient has regular weekly contact and who is available and willing to participate in all 4 sessions of the intervention
- Sufficient visual acuity to read 12-point font
- Sufficient manual dexterity to use scissors
- Ability to hear instructions in a classroom setting
- Ability to read English
- Age 18 years old or greater
Exclusion criteria for patients include:
- Any uncontrolled medical or neurological/neurodegenerative condition (other than AD) that, in the opinion of the Investigator, might be a contributing cause of the subject's cognitive impairment (e.g., substance abuse, vitamin B12 deficiency, abnormal thyroid function, stroke or other cerebrovascular condition, Lewy body dementia, fronto-temporal dementia, head trauma).
- Current active psychiatric illness (e.g., major depression, schizophrenia, etc.)
- Current active seizure disorder.
- Malignancy or carcinoma currently requiring active treatment or progressing off of treatment.
- Recent history (within 1 year) of alcohol abuse or drug abuse.
- Active tobacco use that interferes with visits (e.g., if the patient would need to smoke during the therapy session).
- Use of medications (e.g., narcotics, sedatives, etc.) that lead to drowsiness during the therapy sessions
- Inability to comply with the instructions of the art therapist.
- Other unspecified reasons that, in the opinion of the Investigator make the subject unsuitable for enrollment.
- Prisoners
Inclusion criteria for care partners include:
- Adult 18 years of age or older
- Ability to consent
- Regular weekly contact with the subject diagnosed with Alzheimer's disease
- Availability and willingness to participate in all 4 sessions of the intervention
- Sufficient visual acuity to read 12-point font
- Sufficient manual dexterity to use scissors
- Ability to hear instructions in a classroom setting
- Ability to read English
Exclusion criteria for care partners include:
- Any uncontrolled medical or neurological/neurodegenerative condition sufficient to cause cognitive impairment
- Current active psychiatric illness (e.g., major depression, schizophrenia, etc.)
- Current active seizure disorder.
- Malignancy or carcinoma currently requiring active treatment or progressing off of treatment.
- Recent history (within 1 year) of alcohol abuse or drug abuse.
- Active tobacco use that interferes with visits (e.g., if the care partner would need to smoke during the therapy session).
Use of medications (e.g., narcotics, sedatives, etc.) that lead to drowsiness during the therapy sessions
- Inability to comply with the instructions of the art therapist.
- Other unspecified reasons that, in the opinion of the Investigator make the care partner unsuitable for enrollment.
- Prisoners
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Dementia Participants and Care Partners
Dyads including a participant diagnosed with dementia and the care partner
|
Dyads will take part in a portrait-making project utilizing a collage approach.
Each participant (i.e.
dementia diagnosed individuals and care partners) will be instructed to create a portrait of him/herself.
Participants will be provided with a sample portrait as well as bins of materials.
]The intervention will be administered for 1 ½ hours weekly, at the same day/time, for 4 consecutive weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Impact of Art Therapy on Quality of Dyadic Relationship
Time Frame: Week 1
|
Impact of art therapy on quality of dyadic relationship will be determined using the Dyadic Relationship Scale.
The survey consists of 10 questions with a total score range of 10-40.
The score is a measure of patient and care partner perceptions of their relationship.
Lower scores indicate the perception of a poorer relationship (i.e.
greater strain, lower positive interactions) and higher scores indicate a perceived better relationship (i.e.
lower strain, greater positive interactions).
|
Week 1
|
|
Impact of Art Therapy on Quality of Dyadic Relationship
Time Frame: Week 4
|
Impact of art therapy on quality of dyadic relationship will be determined using the Dyadic Relationship Scale.
The survey consists of 10 questions with a total score range of 10-40.
The score is a measure of patient and care partner perceptions of their relationship.
Lower scores indicate the perception of a poorer relationship (i.e.
greater strain, lower positive interactions) and higher scores indicate a perceived better relationship (i.e.
lower strain, greater positive interactions).
|
Week 4
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Impact of Art Therapy on Dementia Individuals' Self-esteem
Time Frame: Week 1
|
The impact of art therapy on the dementia diagnosed individuals' self-esteem will be determined by the Rosenberg Self-Esteem Scale.
The survey consists of 10 questions with a total score range of 0-30.
The score is a measure of patient self-esteem, with lower scores meaning lower self-esteem and higher scores meaning higher self-esteem.
|
Week 1
|
|
Impact of Art Therapy on Dementia Individuals' Self-esteem
Time Frame: Week 4
|
The impact of art therapy on the dementia diagnosed individuals' self-esteem will be determined by the Rosenberg Self-Esteem Scale.
The survey consists of 10 questions with a total score range of 0-30.
The score is a measure of patient self-esteem, with lower scores meaning lower self-esteem and higher scores meaning higher self-esteem.
|
Week 4
|
|
Impact of Art Therapy on Dementia Individuals' Sense of Stigma
Time Frame: Week 1
|
The impact of art therapy on diagnosed individuals' sense of stigma will be determined by the Stigma Impact Scale.
The survey consists of 20 questions with a total score range of 0-80.
The score is a measure of the patient's perception of stigma, with lower scores indicating lower perceived stigma and higher scores indicating greater perceived stigma.
|
Week 1
|
|
Impact of Art Therapy on Dementia Individuals' Sense of Stigma
Time Frame: Week 4
|
The impact of art therapy on diagnosed individuals' sense of stigma will be determined by the Stigma Impact Scale.
The survey consists of 20 questions with a total score range of 0-80.
The score is a measure of the patient's perception of stigma, with lower scores indicating lower perceived stigma and higher scores indicating greater perceived stigma.
|
Week 4
|
|
Impact of Art Therapy on Care Partner Attitudes Towards Persons with Dementia
Time Frame: Week 1
|
The impact of art therapy on care partner attitudes towards persons with dementia will be determined by the Dementia Attitudes Scale.
The survey consists of 20 questions with a total score range of 20-140.
The score is a measure of care partner attitudes towards patients with dementia.
Lower scores indicate lower knowledge and social comfort with persons with dementia and a higher score indicates greater knowledge and social comfort with persons with dementia.
|
Week 1
|
|
Impact of Art Therapy on Care Partner Attitudes Towards Persons with Dementia
Time Frame: Week 4
|
The impact of art therapy on care partner attitudes towards persons with dementia will be determined by the Dementia Attitudes Scale.
The survey consists of 20 questions with a total score range of 20-140.
The score is a measure of care partner attitudes towards patients with dementia.
Lower scores indicate lower knowledge and social comfort with persons with dementia and a higher score indicates greater knowledge and social comfort with persons with dementia.
|
Week 4
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Darren Gitelman, MD, Wake Forest University Health Sciences
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 26, 2016
Primary Completion (Actual)
August 2, 2022
Study Completion (Actual)
August 2, 2022
Study Registration Dates
First Submitted
December 5, 2024
First Submitted That Met QC Criteria
December 5, 2024
First Posted (Estimated)
December 10, 2024
Study Record Updates
Last Update Posted (Estimated)
December 10, 2024
Last Update Submitted That Met QC Criteria
December 5, 2024
Last Verified
December 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00106942
- 6409 (Other Identifier: Advocate Health Care)
- 2016-102 (Other Grant/Funding Number: James R. and Helen D. Russell Center for Research and Innovation)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dementia
-
Benjamin Rose Institute on AgingNational Institute on Aging (NIA)RecruitingMild Dementia | Moderate DementiaUnited States
-
Yaolin PeiNational Institutes of Health (NIH)RecruitingEnd of Life Decision Making | Dementia Caregivers | Advanced DementiaUnited States
-
Benuvia Therapeutics Inc.MandaraNot yet recruiting
-
University of North Carolina, Chapel HillNational Institute on Aging (NIA)CompletedAlzheimer Dementia | Dementia Alzheimers | CaregiverUnited States
-
Temple UniversityCompletedDementia | Mild Cognitive Impairment | Dementia, Vascular | Dementia, Mixed | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Dementia, MildUnited States
-
Hebrew SeniorLifeActive, not recruitingAging | Alzheimer Dementia | Presenile Alzheimer DementiaUnited States
-
Temple UniversityCompletedDementia | Alzheimer Disease | Mild Cognitive Impairment | Dementia, Vascular | Dementia, Mixed | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Dementia, MildUnited States
-
NYU Langone HealthRecruiting
-
The University of Hong KongNot yet recruiting
-
National Tainan Junior College of NursingCompletedCognitive Impairment | Dementia, Mild | Dementia ModerateTaiwan
Clinical Trials on Art Therapy
-
King Abdullah University HospitalCompletedPTSD - Post Traumatic Stress DisorderJordan
-
Dokuz Eylul UniversityRecruitingAnxiety | Sleep Disturbance | Colorectal Cancer (Diagnosis)Turkey (Türkiye)
-
Hampton VA Medical CenterTerminatedPost-traumatic Stress Disorder | Stress Disorder, Post-TraumaticUnited States
-
University of ZurichRecruitingPosttraumatic Stress Disorder | Pancreas Cancer | Depression, Anxiety | Lower Gastrointestinal Neoplasms BenignSwitzerland
-
Mersin UniversityNot yet recruiting
-
Centre Hospitalier de PerigueuxUniversity Hospital, LimogesRecruitingTherapy-Associated CancerFrance
-
Dr. Sarkis MeterissianThe Cedars Cancer InstituteCompleted
-
Chonbuk National UniversityRecruiting
-
University of DerbyCompletedPerinatal Mental HealthUnited Kingdom